APA
Earl H. M., Hiller L., Howard H. C., Dunn J. A., Young J., Bowden S. J., McDermaid M., Waterhouse A. K., Wilson G., Agrawal R., O'Reilly S., Bowman A., Ritchie D. M., Goodman A., Hickish T., McAdam K., Cameron D., Dodwell D., Rea D. W., Caldas C., Provenzano E., Abraham J. E., Canney P., Crown J. P., Kennedy M. J., Coleman R., Leonard R. C., Carmichael J. A., Wardley A. M. & Poole C. J. (20170824). Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. : The Lancet. Oncology.
Chicago
Earl Helena M, Hiller Louise, Howard Helen C, Dunn Janet A, Young Jennie, Bowden Sarah J, McDermaid Michelle, Waterhouse Anna K, Wilson Gregory, Agrawal Rajiv, O'Reilly Susan, Bowman Angela, Ritchie Diana M, Goodman Andrew, Hickish Tamas, McAdam Karen, Cameron David, Dodwell David, Rea Daniel W, Caldas Carlos, Provenzano Elena, Abraham Jean E, Canney Peter, Crown John P, Kennedy M John, Coleman Robert, Leonard Robert C, Carmichael James A, Wardley Andrew M and Poole Christopher J. 20170824. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. : The Lancet. Oncology.
Harvard
Earl H. M., Hiller L., Howard H. C., Dunn J. A., Young J., Bowden S. J., McDermaid M., Waterhouse A. K., Wilson G., Agrawal R., O'Reilly S., Bowman A., Ritchie D. M., Goodman A., Hickish T., McAdam K., Cameron D., Dodwell D., Rea D. W., Caldas C., Provenzano E., Abraham J. E., Canney P., Crown J. P., Kennedy M. J., Coleman R., Leonard R. C., Carmichael J. A., Wardley A. M. and Poole C. J. (20170824). Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. : The Lancet. Oncology.
MLA
Earl Helena M, Hiller Louise, Howard Helen C, Dunn Janet A, Young Jennie, Bowden Sarah J, McDermaid Michelle, Waterhouse Anna K, Wilson Gregory, Agrawal Rajiv, O'Reilly Susan, Bowman Angela, Ritchie Diana M, Goodman Andrew, Hickish Tamas, McAdam Karen, Cameron David, Dodwell David, Rea Daniel W, Caldas Carlos, Provenzano Elena, Abraham Jean E, Canney Peter, Crown John P, Kennedy M John, Coleman Robert, Leonard Robert C, Carmichael James A, Wardley Andrew M and Poole Christopher J. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. : The Lancet. Oncology. 20170824.